XNAS
FTLF
Market cap86mUSD
Oct 08, Last price
8.70USD
1D
-5.74%
1Q
-22.39%
Jan 2017
7,226.32%
IPO
124.52%
Name
FitLife Brands Inc
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
FitLife Brands, Inc. supplies dietary supplements to health-conscious individuals across the United States and globally. Their extensive product line caters to various needs, encompassing weight management, overall well-being, and athletic performance. This includes specialized formulations designed for professional muscle development, performance-enhancing supplements for fitness enthusiasts, and offerings for men's health, alongside general diet, health, sports nutrition items, energy boosters, and meal replacement options. The company markets its diverse portfolio under well-known brand names such as NDS Nutrition, PMD Sports, SirenLabs, CoreActive, Metis Nutrition, iSatori, BioGenetic Laboratories, and Energize. These products are distributed through a multi-channel approach, including company-franchised stores, a variety of retail outlets (specialty and mass market), and e-commerce platforms. Established in 2005, the company was previously known as Bond Laboratories, Inc., adopting the FitLife Brands, Inc. name in September 2013, and maintains its headquarters in Omaha, Nebraska.
Key people
Independent Chairman of the Board · since 2011
Jenna Sinnett
Chief Operating Officer · since 2015
Patrick Ryan
Chief Retail Officer · since 2016
Interim Chief Executive Officer, Director · since 2018
Grant Robert Dawson
Independent Director · since 2013
Todd Ordal
Independent Director · since 2015
Seth Yakatan
Independent Director · since 2015
Legal address
C/O VCORP SERVICES, LLC
701 S. CARSON STREET
SUITE 200
CARSON CITY, NV 89701
US
701 S. CARSON STREET
SUITE 200
CARSON CITY, NV 89701
US
Headquarters
5214 S 136th Street
Omaha, NE 68137
US
Omaha, NE 68137
US
Previous name
Bond Laboratories, Inc.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||